Phosphodiesterase-type 3 inhibitor potentiates cAMP generation and antiproliferative effects of treprostinil in pulmonary arterial smooth muscle cells from patients with pulmonary hypertension Source: Annual Congress 2010 - Pathobiology of pulmonary hypertension Year: 2010
Sildenafil enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 24s Year: 2002
In vitro effects of vasodilatory drugs on BMPR2-silenced pulmonary microvascular endothelial cell function Source: Virtual Congress 2021 – Pathogenesis and pathophysiology of pulmonary hypertension Year: 2021
Effects of prostacyclin analogous iloprost trometamol on bleomisin induced pulmonary fibrosis in rats Source: Annual Congress 2010 - Experimental approaches in pulmonary fibrosis Year: 2010
Additive protective effects of sacubitril/valsartan and bosentan on vascular remodeling in experimental pulmonary hypertension Source: Virtual Congress 2020 – Experimental approaches to pulmonary hypertension Year: 2020
Inhaled liposomal iloprost extend detectable plasma level and prolong reduction of hypoxia-induced pulmonary hypertension in rat Source: International Congress 2019 – Pulmonary hypertension with lung diseases and experimental pulmonary hypertension Year: 2019
A prostacyclin analogue, iloprost, protects from bleomycin-induced pulmonary fibrosis in mice Source: Annual Congress 2010 - Experimental approaches in pulmonary fibrosis Year: 2010
Effects of iloprost and the phosphodiesterase inhibitor tolafentrine on pulmonary vascular remodelling in chronic experimental pulmonary hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 20s Year: 2003
VIP prevents and reverses monocrotaline-induced PAH: Further protection by combination with bosentan Source: Annual Congress 2010 - Experimental pulmonary hypertension Year: 2010
Protective effect of leukotriene receptor antagonist montelukast in bleomycin induced pulmonary fibrosis Source: Eur Respir J 2006; 28: Suppl. 50, 669s Year: 2006
Dexamethasone induces anti-remodelling effects in rat pulmonary arterial smooth muscle cells Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and cell biology Year: 2012
Tiotropium inhibits acetylcholine-induced generation of proinflammatory microparticles by human pulmonary epithelial cells Source: International Congress 2018 – COPD: immune regulation and therapeutic targets Year: 2018
ACE2 activation improves pulmonary endothelial function and attenuates monocrotaline-induced pulmonary hypertension Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011
Oral administration of a new prostacyclin agonist with thromboxane synthase inhibitory activity improves bleomycin-induced lung fibrosis Source: Annual Congress 2010 - New insights in the treatment of idiopathic pulmonary fibrosis Year: 2010
2-Methoxyestrone inhibits vascular remodeling and attenuates monocrotaline-induced pulmonary hypertension Source: Annual Congress 2008 - Pulmonary vascular biology Year: 2008
α1 -adrenoceptor antagonism does not modify the pulmonary vasoconstrictor effect of dexfenfluramine in the rat Source: Eur Respir J 2001; 18: Suppl. 33, 491s Year: 2001
Mechanisms of vascular endothelial cell injury in response to intermittent and continuous hypoxia exposure and protective effects of anti-inflammatory and anti-oxidant agents Source: International Congress 2019 – Novel methods, diagnostics and biomarkers in chronic lung diseases Year: 2019
Protective effect of cysteinyl leukotriene receptor antagonist montelukast in bleomycin induced pulmonary fibrosis Source: Eur Respir J 2007; 30: Suppl. 51, 111s Year: 2007
Effects of Sildenafil on hypoxic pulmonary vasoconstriction in dogs Source: Eur Respir J 2001; 18: Suppl. 33, 490s Year: 2001
Effects of the NO donor molsidomine on prostacyclin synthase gene expression in rats with chronic hypoxic pulmonary hypertension Source: Eur Respir J 2001; 18: Suppl. 33, 414s Year: 2001